Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis
Jonathan E. Knikman, Tycho A. Wilting, Marta López‐Yurda, Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, Didier Meulendijks, Peter Nieboer, Helga Droogendijk, Geert-Jan Creemers, Caroline M.P.W. Mandigers, Alexander L.T. Imholz, Ron H.J. Mathijssen, Johanneke E.A. Portielje, Liselot Valkenburg‐van Iersel, Annelie Vulink, Marlene H.W. van der Poel, Arnold Baars, Jesse J. Swen, Hans Gelderblom, Jan H.M. Schellens, Jos H. Beijnen, Henk‐Jan Guchelaar, Annemieke Cats
Abstract
PURPOSE: wild-type controls receiving a full fluoropyrimidine dose in a retrospective matched-pair survival analysis. METHODS: wild-type controls treated with a standard dose. Survival analyses were performed using Kaplan-Meier estimates and Cox regression. RESULTS: *2A and c.2846A>T carriers. CONCLUSION: variant carriers. Close monitoring with early dose modifications based on toxicity is recommended, especially for c.1236G>A carriers receiving a reduced starting dose.